Gabor Heltovics

Investing in vision: Innovation in retinal therapeutics and the influence on venture capital investment https://lnkd.in/d2QHx_bH by Dr. Dmitrij Hristodorov, Tim Lohoff, Nanna Lüneborg, Geert-Jan Mulder, Simon J. Clark. Highlights: 1. The acquisition of Gyroscope by Novartis for up to $1.5 Billion in 2022, including an upfront payment of $800 million. It was a landmark deal for the founding investor, Syncona Limited, delivering an impressive ~$424 million upfront return. Other investors in Gyroscope, including Forbion, Sofinnova Investments and T. Rowe Price Associates enjoyed a quick return following their investment into the company in 2021. Regrettably, Novartis has recently announced that further development of GT005 has been stopped. In a press release, Novartis states that “this decision was based on a recommendation from the independent Data Monitoring Committee following an overall risk-benefit assessment of available data from the program studies, which concluded futility criteria had been met. Importantly, no new safety signals were identified” 2) Increasingly clinical-stage programs can be developed by biotech companies on a standalone basis, with increasingly larger financing rounds. Between 2004 and today, the average financing round has almost quadrupled from around $17 M in 2004 to around $63 M in 2022 and 2023 3) The likelihood of drug approval for ophthalmic drugs after a positive Phase 2 read-out is ~47% only and compares unfavorably to several other therapeutic areas. The availability of larger funds provided by VCs to run larger Phase 2 b and/or even pivotal Phase 3 studies will allow us to close this potential gap of innovation in the coming future 4) 9 out of the 15 largest financings were for gene therapy companies 5) The surge of investment has been paralleled by a growing appetite from pharma in the ophthalmology sector, highlighted by the most recent mega-deal, the acquisition of Iveric Bio, An Astellas Compan by Astellas for $5.9 billion. Pharma companies have become aware of the enormous impact and financial success they can generate, as showcased by blockbuster anti-VEGF drugs, such as Lucentis and Eylea

8

🌟 Check out this fascinating post by Theramir Ltd on the future of cancer medicine with microRNAs! The EVmiR® platform offers a targeted approach to cancer therapy, showing promise in inhibiting tumor growth and regulating metastasis. 🚀 #CancerResearch #InnovativeMedicine #Theramir

31

2 hozzászólás

Schedule a meeting with the experts from Discovery at #EACR #biospecimens #genomics #proteomics #IHC #flowcytometry

5

SMALL CAP IDEA: Time to add Hemogenyx Pharma to the watchlist https://lnkd.in/e5xWgbha

19

It's increasingly difficult for biotech companies to secure funding. As a result, biotechs are looking for new ways to communicate their value to investors. Development pipelines are traditionally seen as tools to gain regulatory approval for novel drugs, but this isn't the only role they can play. Pipelines can also be a valuable tool for securing investment. This is because a solid pipeline highlights your understanding of the development process and demonstrates how you aim to overcome certain challenges along the way. In an industry where 90% of drug candidates fail, this is an excellent way to provide investors with some confidence and peace of mind. #Funding #Biotech #VentureCapital #BusinessStrategies

18

1 hozzászólás